SEC Form 4 · Rule 10b5-1 trading plans

Mineralys Therapeutics, Inc. (MLYS)

8Trades filed under a plan
3Plan adoption dates stated
7Quarterly results prints on file
0Trades in the days before a print

In the 2025 filing year, Mineralys Therapeutics, Inc. filed 6 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 3 reporting owners, covering 8 transactions filed under those plans and 79,072 shares. None carries the SEC's own AFF10B5ONE adoption flag; each of the 6 names a plan in a footnote. 7 results prints are on file in the same window, which is what makes the interval below measurable.

Trades filed under a plan in Mineralys Therapeutics, Inc. 8

Plan adoption dates stated in Mineralys Therapeutics, Inc. 3

Quarterly results prints on file in Mineralys Therapeutics, Inc. 7

Trades in the days before a print in Mineralys Therapeutics, Inc. 0

Interval to the next reported results date

For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.

0Within 5 days of a print
0Within 10 days of a print
29Shortest interval, in days
0Trades with no later print on file

Adoption dates, as the filings state them

As the filings state it: “10b5-1 trading plan adopted by the Reporting Person on October 25, 2024”

Reported results dates on file

A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.

Other companies with plan records

Order the document

Every company with plan records →

Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.